Results 1 to 10 of about 32,200 (252)
Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium
Frontiers in Neurology, 2022 The Lewy Body Dementia Association (LBDA) held a virtual event, the LBDA Biofluid/Tissue Biomarker Symposium, on January 25, 2021, to present advances in biomarkers for Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLBs) and ...
Gregory D. Scott +54 more
doaj +3 more sources
Cortical Lewy Body Dementia [PDF]
Behavioural Neurology, 1990 In cortical Lewy body dementia the distribution of Lewy bodies in the nervous system follows that of Parkinson's disease, except for their greater profusion in the cerebral cortex. The cortical tangles and plaques of Alzheimer pathology are often present,
W. R. G. Gibb
doaj +3 more sources
Probable dementia with Lewy body [PDF]
Romanian Journal of Neurology, 2017 V.A. female, 67 years, old admitted in our clinic for neurological assessment because of a Parkinson syndrome, in association with neurocognitive disorder established in a psychiatric service.
Irene Davidescu
doaj +2 more sources
Evidence for divergent cortical organisation in Parkinson’s disease and Lewy Body Dementia [PDF]
Nature CommunicationsDementia is a defining feature of Lewy body disease: its timing and onset distinguish different clinical diagnoses, and its effect on quality of life is profound.
Angeliki Zarkali +7 more
doaj +2 more sources
Annals of Medicine, 1999 Although Lewy body dementia (LBD) has received a considerable amount of interest in the last decade, there still exists a certain level of confusion concerning the clinical and neuropathological features associated with this disorder. According to many researchers, LBD represents a distinct dementing illness with specific clinical features.
Daniel F Brown
exaly +3 more sources
Neuropathology of Lewy body dementia: Lewy-related pathology, α-synuclein oligomers, and comorbid pathologies [PDF]
Molecular NeurodegenerationLewy body dementia is the second most common form of neurodegenerative dementia, following Alzheimer’s disease. This umbrella term encompasses dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD).
Hiroaki Sekiya +3 more
doaj +2 more sources
Neuroinflammation in Lewy body dementia [PDF]
Parkinsonism and Related Disorders, 2015 Neuroinflammation is increasingly recognized as a key factor in the pathogenesis of neurodegenerative conditions. However, it remains unclear whether it has a protective or damaging role. Studies of Alzheimer's disease and Parkinson's disease have provided much of the evidence for inflammatory pathology in neurodegeneration. Here we review the evidence
Ajenthan Surendranathan +2 more
exaly +3 more sources
Research models to study lewy body dementia [PDF]
Molecular NeurodegenerationLewy body dementia (LBD) encompasses neurodegenerative dementias characterized by cognitive fluctuations, visual hallucinations, and parkinsonism. Clinical differentiation of LBD from Alzheimer’s disease (AD) remains complex due to symptom overlap, yet ...
Suelen Lucio Boschen +4 more
doaj +2 more sources
Dementia with Lewy bodies [PDF]
Psychiatry, 1999 Objective: The aim of this paper is to summarise recent clinical and research findings with regard to dementia with Lewy bodies (DLB). Method: A literature review (Medline) was carried out, as well as a review of reports of recent DLB symposia of international meetings and of other relevant papers and data known to the authors.
I, McKeith, J, O'Brien
openaire +14 more sources
Novel Ubiquitin Specific Protease-13 Inhibitors Alleviate Neurodegenerative Pathology
Metabolites, 2021 Ubiquitin Specific Protease-13 (USP13) promotes protein de-ubiquitination and is poorly understood in neurodegeneration. USP13 is upregulated in Alzheimer’s disease (AD) and Parkinson’s disease (PD), and USP13 knockdown via shRNA reduces neurotoxic ...
Xiaoguang Liu +5 more
doaj +1 more source